We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > small-cell lung cancer

News List

AbbVie halts late-stage TAHOE study of Rova-T in small-cell lung cancer firstwordpharma
December 06, 2018
AbbVie on Wednesday announced that it was stopping enrolment of the Phase III TAHOE study assessing rovalpituzumab tesirine, also known as Rova-T, as a second-line treatment for patients with advanced small-cell lung cancer.
AbbVie halts late-stage TAHOE study of Rova-T in small-cell lung cancer firstwordpharma
December 06, 2018
AbbVie on Wednesday announced that it was stopping enrolment of the Phase III TAHOE study assessing rovalpituzumab tesirine, also known as Rova-T, as a second-line treatment for patients with advanced small-cell lung cancer.